AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29587874 — intervention group
Group type: EXPERIMENTAL
Intervention: SUR + BREAKS group (energy surplus with intermittent walking)
Number of subjects: 48
Study 27193480 — intervention group
Group type: EXPERIMENTAL
Intervention: Two implant-supported overdentures
Number of subjects: 52
Study 27193480 — intervention group
Group type: EXPERIMENTAL
Intervention: Four implant-supported overdentures
Number of subjects: 52
Study 25109416 — intervention group
Group type: EXPERIMENTAL
Intervention: Elpenhaler
Number of subjects: 100
Study 25109416 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 100
Study 22520137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 1308
Study 20653227 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants walking around a room
Number of subjects: 0
Study 20653227 — intervention group
Group type: COMPARATOR
Intervention: Participants sitting at a desk
Number of subjects: 0
Study 20653227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of background visual motion and relative movement of sound while sitting at a desk
Number of subjects: 0
Study 18946061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus best supportive care
Number of subjects: 394
Study 18946061 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 394
Study 16210250 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care test for salivary nicotine metabolites
Number of subjects: 100
Study 16210250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no point of care test)
Number of subjects: 100
Study 12226001 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption of fruits and vegetables (highest quintile)
Number of subjects: 27084
Study 12226001 — intervention group
Group type: EXPERIMENTAL
Intervention: High lycopene intake (highest quintile)
Number of subjects: 27084
Study 12226001 — intervention group
Group type: EXPERIMENTAL
Intervention: High lutein/zeaxanthin intake (highest quintile)
Number of subjects: 27084
Study 12226001 — intervention group
Group type: EXPERIMENTAL
Intervention: High β‐cryptoxanthin intake (highest quintile)
Number of subjects: 27084
Study 12226001 — intervention group
Group type: EXPERIMENTAL
Intervention: High total carotenoids intake (highest quintile)
Number of subjects: 27084
Study 12226001 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum β‐carotene levels
Number of subjects: 27084
Study 12226001 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum retinol levels
Number of subjects: 27084
Study 11041405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinetti balance scale (cut-off score of 36 or less)
Number of subjects: 225
Study 11041405 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening positive with Tinetti balance scale
Number of subjects: 225
Study 9214174 — intervention group
Group type: COMPARATOR
Intervention: Austin technique without lateral soft tissue release
Number of subjects: 45
Study 9214174 — intervention group
Group type: EXPERIMENTAL
Intervention: Austin technique with lateral soft tissue release
Number of subjects: 45
Study 8417512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 0
Study 8417512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0
Study 8417512 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Hydralazine + Nitroglycerin)
Number of subjects: 0
Study 2941277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 100 mg
Number of subjects: 32
Study 2941277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg
Number of subjects: 32
Study 2941277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 250 mg (after breakfast)
Number of subjects: 32
Study 2941277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200 mg (20 min infusion)
Number of subjects: 32
Study 2941277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (various doses)
Number of subjects: 32
Study 2941277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (various doses)
Number of subjects: 32
Study 2941277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 250 mg
Number of subjects: 32
Study 30063750 — intervention group
Group type: EXPERIMENTAL
Intervention: Social interaction with robot that voiced an objection against being switched off
Number of subjects: 85
Study 30063750 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional interaction with robot that voiced an objection against being switched off
Number of subjects: 85
Study 30063750 — intervention group
Group type: COMPARATOR
Intervention: Functional interaction with robot that remained silent
Number of subjects: 85
Study 30063750 — intervention group
Group type: COMPARATOR
Intervention: Social interaction with robot that remained silent
Number of subjects: 85
Study 29901903 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose MgSO4 (10 gm)
Number of subjects: 88
Study 29901903 — intervention group
Group type: COMPARATOR
Intervention: Low dose MgSO4 (5 gm)
Number of subjects: 88
Study 24898851 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal focus of attention (interoception)
Number of subjects: 48
Study 24898851 — intervention group
Group type: COMPARATOR
Intervention: External focus of attention (exteroception)
Number of subjects: 48
Study 22244408 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 110
Study 22244408 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia
Number of subjects: 110
Study 20145260 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-encapsulated moxifloxacin
Number of subjects: 22
Study 20145260 — intervention group
Group type: COMPARATOR
Intervention: Over-encapsulated placebo
Number of subjects: 22
Study 20145260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare moxifloxacin
Number of subjects: 22
Study 20145260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) moxifloxacin
Number of subjects: 22
Study 18980516 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded sites
Number of subjects: 24
Study 18980516 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded sites
Number of subjects: 24
Study 18980516 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 24
Study 15735130 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care provider-directed intervention
Number of subjects: 1978
Study 15735130 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1978
Study 12028871 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible coiled stainless steel stent (Freedom Force, Global Therapeutics)
Number of subjects: 44
Study 12028871 — intervention group
Group type: COMPARATOR
Intervention: Stiff tubular stainless steel stent (Crown, Johnson & Johnson)
Number of subjects: 44
Study 10233122 — intervention group
Group type: EXPERIMENTAL
Intervention: Core temperature (Tc)
Number of subjects: 0
Study 10233122 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-surface temperature (Tsk)
Number of subjects: 0
Study 8927272 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 348
Study 8927272 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 348
Study 1801570 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to environmental cues
Number of subjects: 60
Study 1801570 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to negative affective cues
Number of subjects: 60
Study 1801570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum smoking
Number of subjects: 60
Study 31003911 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus cobimetinib (840 mg intravenously every 2 weeks + 60 mg orally once daily for days 1–21 of a 28-day cycle)
Number of subjects: 363
Study 31003911 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy (1200 mg intravenously every 3 weeks)
Number of subjects: 363
Study 31003911 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib (160 mg orally once daily for days 1–21 of a 28-day cycle)
Number of subjects: 363
Study 28268201 — intervention group
Group type: EXPERIMENTAL
Intervention: Asset-based practices
Number of subjects: 71
Study 28268201 — intervention group
Group type: COMPARATOR
Intervention: Needs-based practices
Number of subjects: 71
Study 25830698 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PDT combined with IVR
Number of subjects: 72
Study 25830698 — intervention group
Group type: COMPARATOR
Intervention: Later PDT combined with IVR
Number of subjects: 72
Study 23859672 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of cefazolin
Number of subjects: 20
Study 23859672 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of cefazolin
Number of subjects: 20
Study 21867378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (H)
Number of subjects: 30
Study 21867378 — intervention group
Group type: COMPARATOR
Intervention: No Hypnosis (NH)
Number of subjects: 30
Study 19390749 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of forms (rf) test
Number of subjects: 50
Study 19390749 — intervention group
Group type: COMPARATOR
Intervention: Assessment by speech and language therapists (SLT)
Number of subjects: 50
Study 19390749 — intervention group
Group type: EXPERIMENTAL
Intervention: rf-test (test-retest)
Number of subjects: 50
Study 19390749 — intervention group
Group type: EXPERIMENTAL
Intervention: rf-test performance
Number of subjects: 50
Study 17721966 — intervention group
Group type: EXPERIMENTAL
Intervention: TRiM training
Number of subjects: 0
Study 17721966 — intervention group
Group type: COMPARATOR
Intervention: Normal military support networks
Number of subjects: 0
Study 17721966 — intervention group
Group type: COMPARATOR
Intervention: General health
Number of subjects: 0
Study 15088127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous interleukin 2 (IL-2) and interferon alpha (IFN-alpha) alone (n = 23)
Number of subjects: 49
Study 15088127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous interleukin 2 (IL-2) and interferon alpha (IFN-alpha) in combination with histamine dihydrochloride (n = 26)
Number of subjects: 49
Study 15088127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy (IL-2 and IFN-alpha)
Number of subjects: 49
Study 11418230 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment (for those with high PRL response)
Number of subjects: 17
Study 11418230 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment (for those with low PRL response)
Number of subjects: 17
Study 9876958 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg xanomeline tartrate three times daily (t.i.d.)
Number of subjects: 343
Study 9876958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 9876958 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAS-cog
Number of subjects: 343
Study 9876958 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTB
Number of subjects: 343
Study 7976162 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.6 mg kg‐1 during balanced anesthesia (nitrous oxide and fentanyl)
Number of subjects: 40
Study 7976162 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.6 mg kg‐1 during halothane anesthesia
Number of subjects: 40
Study 7976162 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.9 mg kg‐1 during balanced anesthesia (nitrous oxide and fentanyl)
Number of subjects: 40
Study 7976162 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.9 mg kg‐1 during halothane anesthesia
Number of subjects: 40
Study 7976162 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide 0.9 mg kg‐1 during anesthesia with nitrous oxide, oxygen, and isoflurane
Number of subjects: 40
Study 7976162 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 2514694 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolande N (modified glibenclamide formulation)
Number of subjects: 12
Study 2514694 — intervention group
Group type: COMPARATOR
Intervention: Marketed standard preparation (glibenclamide)
Number of subjects: 12
Study 1104076 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytetracycline (Imperacin-I.C.I.)
Number of subjects: 259
Study 1104076 — intervention group
Group type: COMPARATOR
Intervention: Tetrabid-Organon (sustained-release tetracycline hydrochloride)
Number of subjects: 259
Study 30814028 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir–ritonavir
Number of subjects: 1266
Study 30814028 — intervention group
Group type: COMPARATOR
Intervention: lamivudine
Number of subjects: 1266
Study 27876790 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-antagonist spironolactone
Number of subjects: 101
Study 27876790 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress induction with cortisol increase
Number of subjects: 101
Study 27876790 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 101
Study 26667790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mediofrontal stimulation with double-cone-coil (2000 stimuli, 10 Hz) followed by left temporo-parietal stimulation with figure-of-eight-coil (2000 stimuli, 1 Hz)
Number of subjects: 40
Study 26667790 — intervention group
Group type: COMPARATOR
Intervention: Left dorsolateral-prefrontal-cortex stimulation with figure-of-eight-coil (2000 stimuli, 10 Hz) followed by temporo-parietal stimulation with figure-of-eight-coil (2000 stimuli, 1 Hz)
Number of subjects: 40
Study 23339145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing minilaparoscopic radical hysterectomy plus pelvic lymphadenectomy
Number of subjects: 87
Study 23339145 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery
Number of subjects: 87
Study 23339145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing minilaparoscopic radical hysterectomy
Number of subjects: 87
Study 23339145 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (last 10 procedures)
Number of subjects: 87
Study 22034119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi exercise (n = 80), 18 40‐minute sessions over a 10‐week period delivered in a group format by a qualified instructor.
Number of subjects: 160
Study 22034119 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n = 80), continued with their usual health care.
Number of subjects: 160
Study 18714620 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 60
Study 18714620 — intervention group
Group type: COMPARATOR
Intervention: Traditional continuous intravenous infusion
Number of subjects: 60
Study 16441475 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 100
Study 16441475 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-electrolyte solution (PEG-ELS)
Number of subjects: 100
Study 12940870 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones from red clover (approximately 50 mg/day for 4 weeks)
Number of subjects: 16
Study 12940870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10741114 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml of Iopamiron 300 mgI/ml (group 1)
Number of subjects: 87
Study 10741114 — intervention group
Group type: COMPARATOR
Intervention: 2 ml/kg of Iopamiron 300 mgI/ml (group 2)
Number of subjects: 87
Study 8885206 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein‐sparing modified fast diet
Number of subjects: 44
Study 8885206 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 1396619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg daily
Number of subjects: 26
Study 1396619 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 10 mg daily
Number of subjects: 26
Study 1396619 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily
Number of subjects: 26
Study 1396619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 26
Study 2865710 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol (0.5% and 1%) twice daily
Number of subjects: 391
Study 2865710 — intervention group
Group type: COMPARATOR
Intervention: Timolol (0.5%) twice daily
Number of subjects: 391
Study 29747594 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic referral / ongoing treatment (Treated Group)
Number of subjects: 79
Study 29747594 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (No Treatment Group)
Number of subjects: 79
Study 29747594 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoys (women without 'Booking GDM')
Number of subjects: 79
Study 27173785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (POM + LoDEX)
Number of subjects: 302
Study 24943550 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Mobile Application Programme (M.A.P.)
Number of subjects: 40
Study 24943550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 22650123 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and Tolterodine
Number of subjects: 120
Study 22650123 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 120
Study 22650123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 120
Study 22650123 — intervention group
Group type: COMPARATOR
Intervention: Control (Pethidine and Anisodamine)
Number of subjects: 120
Study 20736728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest online discussion activity with a faculty e‐moderator
Number of subjects: 0
Study 20736728 — intervention group
Group type: COMPARATOR
Intervention: Control group (students without access to the pretest online discussion)
Number of subjects: 0
Study 18441454 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 34
Study 18441454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16235460 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of hyperbaric bupivacaine combined with 2 mg of midazolam intrathecally (M+M)
Number of subjects: 60
Study 16235460 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg of hyperbaric bupivacaine (M)
Number of subjects: 60
Study 14675879 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atriotomy (Group 1)
Number of subjects: 27
Study 14675879 — intervention group
Group type: COMPARATOR
Intervention: Lateral cavatomy (Group 2)
Number of subjects: 27
Study 10973391 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal values (cardiac index >4.5 L/min/m2, ratio of transcutaneous oxygen tension to fractional inspired oxygen >200, oxygen delivery index >600 mL/min/m2, and oxygen consumption index >170 mL/min/m2)
Number of subjects: 75
Study 10973391 — intervention group
Group type: COMPARATOR
Intervention: Normal values of systolic blood pressure, urine output, base deficit, hemoglobin, and cardiac index (control group)
Number of subjects: 75
Study 10973391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (optimal and control) who achieved optimal values
Number of subjects: 75
Study 10973391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (optimal and control)
Number of subjects: 75
Study 8993081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine; specific dosage and duration not mentioned
Number of subjects: 0
Study 8993081 — intervention group
Group type: COMPARATOR
Intervention: Placebo; specific dosage and duration not mentioned
Number of subjects: 0
Study 1620908 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet-induced airway vibration (10 Hz, 25 psi)
Number of subjects: 14
Study 1620908 — intervention group
Group type: COMPARATOR
Intervention: Sham pulsations (placebo treatment)
Number of subjects: 14
Study 4022342 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 245
Study 30409551 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety symptoms (dichotomously assessed) in participants aged 65 years and older
Number of subjects: 918
Study 30409551 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anxiety symptoms
Number of subjects: 918
Study 27892594 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 10 mg/ml (10 mg)
Number of subjects: 120
Study 27892594 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 10 mg/ml (20 mg)
Number of subjects: 120
Study 27892594 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 10 mg/ml (30 mg)
Number of subjects: 120
Study 26614144 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg(‐1) induction, 6‐10 mg kg(‐1)h(‐1) maintenance
Number of subjects: 30
Study 26614144 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.5 mg kg(‐1) induction, 0.5 mg kg(‐1) maintenance
Number of subjects: 30
Study 22818226 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide care education programme (2-hour duration)
Number of subjects: 61
Study 22818226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education programme)
Number of subjects: 61
Study 22185846 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabadariffa extract (SHE) standardized 10 mg of anthocyanins
Number of subjects: 104
Study 22185846 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabadariffa extract (SHE) standardized 20 mg of anthocyanins for 12 weeks
Number of subjects: 104
Study 22185846 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg
Number of subjects: 104
Study 19369457 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib or Indomethacin for 7 days
Number of subjects: 339
Study 19369457 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Allopurinol users
Number of subjects: 339
Study 19369457 — intervention group
Group type: COMPARATOR
Intervention: Non-users of Allopurinol
Number of subjects: 339
Study 17119520 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 24
Study 17119520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 24
Study 15094256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 50
Study 15094256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50